Drug Trial Radar · NCT07925775
Immunogenicity and Safety of SYS6057 in the Participants Aged 18 Years and Above
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
96
Planned (sponsor's estimate)
Start
Oct 31, 2026
Primary completion
Mar 31, 2027
Study completion Feb 28, 2028
Sponsor
- Lead sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Human respiratory syncytial virus (RSV) is an enveloped, non-segmented, single-stranded negative-sense RNA virus. It is one of the most common pathogens causing acute lower respiratory infection (ALRI) in infants, young children, and older adults worldwide. Vaccination with an RSV vaccine can prevent lower respiratory tract disease caused by RSV infection. We are conducting a randomized, blinded, placebo-controlled, Phase I clinical trial to evaluate the safety and immunogenicity of SYS6057 (Recombinant Respiratory Syncytial Virus Vaccine (CHO cell)) in individuals aged 18 years and older.
Conditions
- Lower Respiratory Tract Disease Caused by RSV Infection
Interventions
Investigational vaccine low doseBiological
Investigational vaccine low dose
Investigational vaccine high doseBiological
Investigational vaccine high dose
PlaceboBiological
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- solicited adverse eventsTime frame: within 14 days post vaccination
- unsolicited adverse eventsTime frame: within 30 days post vaccination
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.